Who
Adam R. Craig
Executive Chairman
Company insider
Files Form 4 as: Executive Chairman, X4 Pharmaceuticals; President and CEO, Cti Biopharma; EVP, Development & CMO, Sunesis Pharmaceuticals; VP and Chief Medical Officer, Innovive Pharmaceuticals.
In numbers
- Trades disclosed
- 111
- Buys
- 4
- Sells
- 15
- Bought
- $295K
- Sold
- $5.5M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 29 Jun 2006
- Last trade
- 16 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 19 Oct 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $12K4,600 at $2.58 | filing |
| 12 Aug 2026filed 13 Aug 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $211K47,436 at $4.44 | filing |
| 12 Aug 2026filed 13 Aug 2026 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $211K47,436 at $4.44 | filing |
| 29 Oct 2025filed 31 Oct 2025 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,329,154 at $0.00 | filing |
| 23 Oct 2025filed 27 Oct 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $250K86,206 at $2.90 | filing |
| 14 Aug 2025filed 14 Aug 2025 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —529,201 at $0.00 | filing |
| 14 Aug 2025filed 14 Aug 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —289,881 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,609,873 at $0.00 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —1,200,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —450,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —475,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —600,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —470,054 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —2,320,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —800,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —1,115,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —900,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharma | SEC FORM 4 Code U | $286K31,470 at $9.10 | filing |
| 14 Mar 2023filed 16 Mar 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 24 Jan 2023filed 26 Jan 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code M | —83,200 at $0.00 | filing |
News
Insider Buying: X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Acquires $11,868.00 in StockXFOR · tickerreport.com · 22 Oct 2026X4 Pharmaceuticals Secures Up to $150MM Senior Debt Facility with K2 HealthVentures - NewsXFOR · abladvisor.com · 12 Oct 2026
0 headlines in the last 90 days name Adam R. Craig; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.